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Introduction
In recent years, biomaterials have been em-
ployed increasingly for sustained delivery applica-
tions to enhance drug safety and efficacy as well as 
to improve patient compliance. Among biomateri-
als, nanomaterials have received considerable inter-
est in the pharmaceutical field. At the nanometer 
scale, these structures match typical sizes of natural 
functional units in living organisms, thus allowing 
them to interact with biomolecules1. Most of the 
nanomaterials used in controlled drug delivery in-
volve non-toxicity, immunogenicity and biorecogni-
tion, as well as the overcoming of obstacles arising 
from low drug solubility, degradation, fast clearance 
rates, relatively short-lasting biological activity and 
inability to cross biological barriers2.
Nanoparticles have been widely exploited in 
the pharmaceutical industry for controlling drug re-
lease due to fundamental changes related to the par-
ticle surface and optical properties3–5. Nanoparticu-
late delivery systems of small molecule drugs have 
the potential power to enhance drug stability and 
increase the duration of the therapeutic effect. 
Nanoparticles prepared from natural, synthetic 
polymers or lipids have been developed to over-
come the enzymatic barrier6–8. Among them, algi-
nate and β-cyclodextrin have provoked great interest 
because they satisfy almost all the necessary proper-
ties of a material for drug delivery nanocarriers.
Alginate (ALG) is a biodegradable polymer 
used as a suspending agent, a gelling agent, and a 
colloid stabilizer. It is extracted from brown sea 
weed and is composed of alternating blocks of 1–4 
linked α-L-guluronic and β-D-mannuronic acid resi-
due (Fig. 1a). A reversibly aqueous alginate gel may 
be formed in the presence of divalent ions at room 
temperature9. Alginate-based nanoparticles may be 
obtained easily by ionotropic gelation method. In 
this method, hydrogel beads, also called gelispheres, 
are formed from cross-linking between alginate 
solution and counter ions such as Ca2+. Drug mole-
cules are commonly distributed into the gelispheres 
to form a three-dimensional lattice of ionically 
cross-linked moiety before the drug-loaded nanopar-
ticles are generated10. Studies on alginate-nanoparti-
cle materials have increased greatly over the past 
decade11–15.
β-Cyclodextrin (β-CD) is a cyclic oligosaccha-
ride consisting of seven (α-1,4)-linked α-D-glucopy-
ranose units as shown in Fig. 1b, resulting in the 
formation of toroidal molecules with internal hy-
drophobic cavities and external hydrophilic surface. 
The most common pharmaceutical application of 
β-CD has been to enhance the solubility, stability, 
safety and bioavailability of drug molecules16. In 
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aqueous solutions, β-CD can form inclusion com-
plexes with many drugs by taking up the drug mol-
ecule or some lipophilic moiety of the molecule, 
into the central cavity and no covalent bonds are 
formed or broken during complex formation. β-CD 
has been an attractive building block for various 
types of drug delivery systems due to its favorable 
toxicological profile, inherent ability to partly or 
completely retain drug molecules and protect them 
from the external environment17–19. In particular, 
Skiba et al. 20 demonstrated that β-CD derivatives 
could interact with Ca2+ ions in an electrostatic man-
ner as non-specific adsorption. Therefore, Ca2+ ion 
can be used as a bridge ion between negatively 
charged elements and β-CD compounds.
Ketoprofen is one of the propionic acid classes 
of non-steroidal anti-inflammatory drugs with anal-
gesic, antipyretic effects, and used in the treatment 
of rheumatoid arthritis21,22. Ketoprofen structure is 
shown in Fig. 1c. Solubility and bioavailability of 
ketoprofen, a poorly water-soluble drug, can be im-
proved by complexation with β-CD as a drug carri-
er23,24. However, studies on ketoprofen delivery 
nanomaterials are presently limited.
In recent years, β-CD and its derivatives encap-
sulated into micro-systems of alginate/polymer have 
been widely investigated in drug delivery applica-
tion12,25,26. However, nanoparticles containing both 
ALG and β-CD have not been reported in literature. 
In this paper, we describe the preparation and char-
acterization of a new nanoparticle containing the 
two above components as a drug delivery system. 
In order to evaluate incorporation and delivery from 
such a system, ketoprofen was chosen as an exam-
ple of BCS class II drug (according to WHO Guid-
ance, low solubility and high permeability)27,28.
Experimental
Materials
β-Cyclodextrin, sodium alginate and ketopro-
fen were purchased from Bodi Chemical Co. (Tian-
jin, China), Shanghai Chemical Co. Ltd (China) and 
Merck (Germany), respectively. All other chemicals 
were of AR grade and used as received without fur-
ther purification. Distilled water and magnetic stir-
rer were used throughout.
Preparation of blank β-cyclodextrin/alginate 
nanoparticles
β-CD/ALG nanoparticles were spontaneously 
obtained via ionotropic gelation method between 
the positively charged ALG/Ca2+ gelispheres and 
the negatively charged β-CD. 0.42–1.47 mL of 
aqueous calcium chloride (10.05 mg mL–1) was 
added dropwise to 3.30 mL of aqueous sodium algi-
nate (9.00 mg mL–1) under stirring for 30 minutes. 
Then, 2 mL of β-CD solution (0.99 – 14.85 mg mL–1) 
was added dropwise into the calcium alginate pre-
gel and stirred for an additional hour. The gel solu-
tion was equilibrated overnight to allow formation 
of nanoparticles in uniform size. The nanoparticles 
were separated by centrifugation (EBA20S-Hettich 
Germany, 8,000 g for 30 min, 30 °C) and then 
freeze-dried to yield the product.













Preparation of ketoprofen loading 
β-cyclodextrin/alginate nanoparticles
A constant volume (0.36 mL) of ketoprofen in 
an ethanol/water mixture (1:1, 1.10 mg mL–1) was 
added to 0.7 mL of calcium chloride solution (10.05 
mg mL–1). Nanoparticles were prepared as method of 
blank β-CD/alginate nanoparticles with various con-
centrations of β-CD solution (0.99 – 2.97 mg mL–1).
F i g .  1  – Chemical structures of sodium alginate (a), β-cyclo-
dextrin (b) and ketoprofen (c)
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Morphology and structure characterization 
of nanoparticles
The morphology of nanospheres was studied 
by scanning electronic microscopy (SEM) using 
JSM7401F (Japan). The samples were lyophilized 
and then mounted on metal stubs, gold coated under 
vacuum before examination. The nanoparticles size 
was measured by transmission electron microscope 
(TEM, Hitachi H8100 with the acceleration 200 kV, 
LaB6 source of electrons, resolution 0.14 nm).
Fourier transform infrared (FTIR) spectra of 
blank and loaded nanoparticles were taken with 
KBr pellets on a FTIR spectrometer (Equinox 55 IR 
– Bruker (Germany)). The same was obtained for 
alginate, β-CD, ketoprofen as standards.
Drugs association efficiency and loading efficiency
The association efficiency was determined in-
directly after separation of nanoparticles from the 
aqueous medium containing nonassociated drug. 
The drug was obtained from the separated solution 
by extraction with diethyl ether. The amount of 
drug associated with the particles was calculated by 
the difference between the total amount used to pre-
pare the particles and the amount of drug present in 
the aqueous phase after centrifugation.
 
A difference between the total amount of drug 
and the amount of residual nonassociated drug as a 
percent of total nanoparticle dry mass is determined 
as loading efficiency. Dry mass was obtained by 
freeze-drying an aliquot of hydrated nanoparticles.
 
Quantitative analysis of ketoprofen
Ketoprofen was assayed by reversed-phase liq-
uid chromatography (RP-HPLC) using an Agilent 
HPLC system (Agilent 1100, USA) equipped with 
UV detector and a ZORBAX SB – C18. For prepara-
tion of standard solutions, a standard solution was 
prepared by diluting a stock solution at a concentra-
tion of 10 mg mL–1 in methanol. The standard solu-
tions were prepared at concentrations of 4.0, 2.0, 1.0 
and 0.5 mg mL–1. For preparation of sample solu-
tions, the supernatant which was obtained by centri-
fuging nanoparticle solutions was extracted with di-
ethyl ether three times and the residue was dissolved 
in methanol after evaporation of diethyl ether.
Association efficiency




total amount of drug
⋅100 %
Loading efficiency




total dry weight of nanoparticles
⋅100 %
Drug release profiles
Ketoprofen release studies were performed by 
stirring 10 mg dried nanoparticles in 10 mL of phos-
phate buffer solutions (pH 5.0 and 7.4) at 37 °C. At 
appropriate intervals, the samples were separated by 
centrifugation (8,000g for 30 min, 30 °C) and the 
amount of drug released from the nanoparticles was 
evaluated by HPLC as described above. The release 







To determine the mechanism of ketoprofen re-








Where Mt/M∞ is the fractional drug release, t is 
the release time, k is a kinetic constant characteris-
tic of the system, and n is the diffusional exponent 
which is indicative of the transport mechanism. 
This equation is useful for a generalized analysis of 
release data, although it may only be used for up to 
60 % of the drug released30. The fitting model was 
conducted with OriginPro 8.5 software.
Results and discussion
Preparation and structure characterization 
β-cyclodextrin/alginate nanoparticles
Preparation of β-CD/ALG nanoparticles was 
carried out by simple ionotropic gelation method. 
The hydrogel beads were formed between Ca2+ solu-
tion and aqueous alginate solution. β-CD drops were 
diffused into a three-dimensional lattice of the ioni-
cally crosslinking gel. In order to study structure of 
formation of nanoparticles, prior to incorporation of 
the gel and β-CD suspension, morphological infor-
mation of the distinct suspension was observed by 
SEM (Fig. 2). The images confirmed that both indi-
vidual components, the alginate/Ca2+ gel and β-CD, 
had micrometer size with a disjointed composition. 
After the incorporation was performed, the distinct 
spherical particles with solid dense structure were 
observed. Nanoparticle sizes were less than 100 nm 
according to SEM image (Fig. 2c).
The β-CD/ALG/Ca2+ nanoparticles might be 
formed by electrostatic interactions in solution ac-
cording to polyelectrolyte complexes mechanism as 
illustrated in Fig. 3. The mechanism is based on 
electrostatic interactions between the oligosaccha-
ride and the oppositely charged ionic crosslinker31,32. 
In this nanoparticle, ion Ca2+ of the hydrogel beads 
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played a role as a bridge ion interacting with the 
β-CD compounds by virtue of its charge in an elec-
trostatic manner20. These complexes resemble ionic 
cross-linking, since non-permanent networks are 
formed that are more sensitive to changes in envi-
ronmental conditions.
In order to determine conditions suitable for 
the formation of nanoparticles, in the first step, we 
studied formation of nanoparticles with different 
Ca2+/ALG w/w ratios in the presence of β-CD. Dif-
ferent volumes of calcium chloride (10.07 mg mL–1) 
were added into the constant volume of ALG solu-
tion (9.0 mg mL–1) to obtain Ca2+/ALG ratios from 
1:2 to 1:7 (w/w). In the presence of β-CD, a high 
amount of Ca2+ ion with 1:2 to 1:3 w/w ratios gave 
the unstable nanoparticles the tendency to agglom-
erate due to increased electrostatic interaction be-
tween Ca2+ ion and β-CD compounds28. Meanwhile, 
the high amount of ALG with 1:6 to 1:7 w/w ratios 
could not generate the formation of nanoparticles. 
As a result, Ca2+/ALG ratios for formation of 
nanoparticles in the presence of β-CD were opti-
mized from 1:4 to 1:5. Alternatively, 1:4.2 w/w 
Ca2+/ALG ratio was finally chosen for further study.
The aim of the next step was to investigate the 
effect of β-CD concentration on size and yield of 
product nanoparticles. The results showed that 
β-CD concentration influenced the size of the re-
sulting nanoparticles (Table 1). In the case of high 
β-CD concentration (14.85 mg mL–1), due to ag-
glomeration of individual nanoparticles, the ob-
served nanoparticles possessing size less than 100 
nm could not be obtained. At 1/4.2/0.42 ratio, a 
highest product yield obtained with a nanoparticle 
size less than 100 nm was 90.1 %. Therefore, these 
ratios would be used for further studies on the drug 
loading nanoparticles.
Ta b l e  1  – Effect of β-CD concentration on nanoparticle 











0 1/4.2/0 >1000 –
1.0 1/4.2/0.28 < 100 84.7 ± 2.5
 1.49 1/4.2/0.42 < 100 90.1 ± 0.8
 2.97 1/4.2/0.84 < 100 75.0 ± 5.1
14.85 1/4.2/4.2 > 100 41.7 ± 1.5
Preparation and structure characterization 
of drug loading β-cyclodextrin/alginate 
nanoparticles
To investigate whether these nanocarriers could 
be used advantageously for hydrophobic drug deliv-
ery, we used ketoprofen as a model drug for studies 
of nanoparticle structure and drug release. The 
preparation of ketoprofen-loaded β-CD/ALG nano-
F i g .  2  – Scanning electron micrographs of β-cyclodextrin (a), alginate/Ca2+ (b), and ALG/ β-CD nanoparticles with Ca2+/ALG/β-CD 
w/w/w ratio of 1/4.2/0.28 (c)
F i g .  3  – Mechanism for formation of β-cyclodextrin/alginate 
nanoparticles
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particles is actually difficult because ketoprofen is a 
hydrophobic drug, while the β-CD/ALG nanoparti-
cles are hydrophilic systems. Precipitation process 
of water-miscible organic solvents could occur in 
an aqueous phase as discrete spherical particles. 
However, a successful entrapment was achieved by 
dissolving the drug in an alcohol/water mixture 
(1:1) prior to its incorporation into the calcium 
chloride solution.
Electron microscopy analysis confirmed the 
presence of nanoparticles and provided morpholog-
ical information of ketoprofen-loaded β-CD/ALG 
nanoparticles (Fig. 4). Thus, the SEM image (Fig. 
4a) showed the morphology of the drug-loaded 
nanoparticle to be solid dense. Additionally, 
nanoparticles possessing a bunch-like structure with 
sizes 50 – 80 nm were seemingly formed from ag-
glomeration of smaller nanosized units.
FT-IR spectra were analysed to characterize the 
potential interactions in the nanoparticles. FT-IR 
spectra of alginate, β-CD, blank, and ketopro-
fen-loaded nanoparticles and ketoprofen are shown 
in Fig. 5. In the spectrum of sodium alginate, the 
broad band at 3430 cm–1 might be due to OH groups; 
the peaks near 1635 cm–1 and 1419 cm–1 were as-
signed to symmetric and asymmetric stretching vi-
bration of COO– groups, respectively. The bands 
around 1050 cm–1 (C–O–C stretching) are attributed 
to its saccharide structure. The absorption band 
characteristics for β-CD were observed at 3340 
cm−1, 2928 cm−1, 1157 cm–1, and 1029 cm–1,which 
correspond to the symmetrical and asymmetrical 
stretching of OH, CH, C–C groups and bending vi-
bration of O–H groups, respectively. After the reac-
tion with alginate, the OH stretching vibration at 
3340 cm−1 of β-CD shifts to 3430 cm–1 and the peaks 
at 1157 cm–1, and 1029 cm–1 shifted similarly by a 
few cm–1. The peaks of ketoprofen at 1697 cm–1 
(C=O stretching of acid group) and 1617 cm–1 (C=O 
stretching of acid group) also appeared in the FT-IR 
spectra of the drug-loaded nanoparticles.
Taking into account blank β-CD/ALG nanopar-
ticle results, we selected three Ca2+/ALG/β-CD ra-
tios (1/4.2/0.28, 1/4.2/0.42 and 1/4.2/0.84 w/w/w), 
which created the nanoparticle sizes smaller than 
100 nm, for further studies aimed at investigating 
the effect of β-CD concentration used to prepare the 
nanoparticles on loading efficiency and association 
efficiency of ketoprofen. The results are shown in 
Table 2. Increasing the amount of β-CD led to an 
increase in the loading efficiency and association 
efficiency values of ketoprofen. This could be ex-
plained by the fact that β-CD molecules formed in-
clusion complexes with ketoprofen by taking up the 
ketoprofen molecule into the central cavities.
Ta b l e  2  – Effect of β-CD concentration on loading efficiency 
and association efficiency of ketoprofen into the 







1/4.2/0.28 1.9 ± 0.1 40.2 ± 1.8
1/4.2/0.42 4.3 ± 0.2 45.4 ± 2.9
1/4.2/0.84 5.7 ± 0.2 50.7 ± 1.3
F i g .  4  – Scanning electron micrograph (a) and transmission electron micrograph (b x30000); (c x100000) of ketoprofen-loaded 
nanoparticles with Ca2+/ALG/β-CD w/w/w ratio of 1/4.2/0.42
F i g .  5  – FTIR spectra of sodium alginate, β-cyclodextrin, 
blank nanoparticles, ketoprofen-loaded β-CD/ALG 
nanoparticles, ketoprofen
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Release properties
Release curves of ketoprofen from drug-loaded 
β-CD/ALG nanoparticles at various pH values at 
37 °C as a function of time are shown in Fig. 6. It 
can be seen that ketoprofen released from β-CD/
ALG nanoparticles was 69 % at pH 5.0 and 57 % at 
pH 7.4 within 4 h. This difference indicated that the 
drug release properties of β-CD/ALG nanoparticles 
are pH sensitive. As seen, at pH 7.4 drug was re-
leased only 27 % within the first two hours and then 
above 50 % within the next two hours. This showed 
that ketoprofen not only protected drug loss but also 
controlled drug release in a neutral environment. A 
faster release occurred at pH 5.0. Within the first 
two hours, more than half of the ketoprofen was re-
leased at pH 5.0. The initial burst release results in 
the light acid medium seem to indicate that a signif-
icant amount of ketoprofen had associated with 
nanoparticles by electrostatic interaction forces.
To investigate more precisely the mechanism 
of the ketoprofen release from nanoparticles, the re-
sults were analysed according to Ritger–Peppas 
equation. Moreover, according to this equation, the 
regression coefficient (R2) was above 0.90 and the 
values of the release exponent (n) for spheres were 
between 0.45 and 0.85 in both pH values (Table 3). 
This means that drug release followed both diffu-
sion-controlled drug release and swelling-controlled 
drug release (anomalous transport)33. Besides, there 
was a significant difference between the k values 
when compared as a function of the medium. The 
drug profiles in light acid showed significantly 
higher k value than in the neutral one, which is con-
sistent with a faster release. These results confirm 
that acid medium could reduce the electrostatic in-
teractions.
Conclusion
A new nanocarrier containing alginate and 
β-cyclodextrin as a drug delivery system is first pre-
pared by an ionotropic gelation technique. Ketopro-
fen, as a hydrophobic drug, was successfully en-
trapped within β-CD/ALG nanoparticles. The final 
composition of the nanoparticles can be modified 
by controlling the formulation conditions. Further 
studies on this nanosystem loading of other import-
ant drugs are in progress.
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